Background: The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), disease progression and magnetic resonance imaging (MRI) activity, with a favorable safety profile in relapsing multiple sclerosis (RMS) patients.
Objective: The purpose of this study was to report the effects of teriflunomide on ARR and disability progression in pre-specified subgroups.
Methods: RMS patients (n=1088) were randomized to placebo or teriflunomide, 7 mg or 14 mg, once daily, for 108 weeks. Subgroup analyses were performed for ARR and disability progression by baseline demographics (gender, race, age), disease characteristics (Expanded Disability Status Scale (EDSS) strata, relapse history, multiple sclerosis (MS) subtype), MRI parameters (gadolinium-enhancing lesions, total lesion volume) and prior use of MS drugs. A generalized estimating equation method and Cox regression model were used to assess consistency of the treatment effect across subgroups, utilizing a treatment-by-subgroup interaction test for each factor separately.
Results: Reductions in ARR and disability progression were consistent across subgroups in favor of teriflunomide, with no treatment-by-subgroup interaction test reaching statistical significance.
Conclusion: The positive effects of teriflunomide were demonstrated consistently across subgroups in TEMSO.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573676 | PMC |
| http://dx.doi.org/10.1177/1352458512450354 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of mitochondrial DNA variants and dysfunction in the pathogenesis and progression of multiple sclerosis.
Mitochondrion
December 2024
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS). The etiology of MS remains elusive, with a complex interplay of genetic and environmental factors contributing to its pathogenesis. Recent studies showed mitochondrial DNA (mtDNA) as a potential player in the development and progression of MS.
View Article and Find Full Text PDFEvaluation of myelin content in the spinal cord of patients with multiple sclerosis: A positron emission tomography study.
Mult Scler Relat Disord
December 2024
Laboratory of Nuclear Medicine (LIM43), Department of Radiology and Oncology, Faculdade de Medicina-FMUSP, Universidade de São Paulo, São Paulo 05403-911, SP, Brazil. Electronic address:
Background: Multiple sclerosis (MS) is divided into Relapsing-Remitting (RRMS) and Progressive (PMS) phenotypes, both associated with spinal cord (SC) damage. MS-related disability and SC atrophy are not yet fully understood and can differ across phenotypes. A combined approach using Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) could provide a broader understanding of myelin changes in the cervical SC (CSC) in different MS phenotypes and the associations with disability.
View Article and Find Full Text PDFThe effects of Neurodynamic Mobilization exercises on upper extremity pain, muscle strength, and functions in patients with multiple sclerosis: A randomised controlled, single blinded study.
Mult Scler Relat Disord
December 2024
Kahramanmaras Sutcu Imam University, Faculty of Medicine, Department Of Neurology, Onikisubat, Kahramanmaras, Turkey. Electronic address:
Backround: Manual therapy techniques are available for pain management in Multiple Sclerosis (MS); however, the results of neurodynamic mobilization (NM) are not known. The aim of this study was to investigate the effects of NM exercises on pain, muscle strength and upper extremity functions in MS patients.
Methods: Patients aged between 18 and 65 years diagnosed with Relapsing Remitting (RR) MS (n = 31) according to McDonald 2010 diagnostic criteria were included in the study.
Corrigendum to "Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels are B cell depletion with Ocrelizumab" [J. Neuroimmunol. 339:578502 (2024)].
J Neuroimmunol
December 2024
Versiti Blood Research Institute, Milwaukee, WI, USA; Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address:
[Quality of life of patients with multiple sclerosis in the Smolensk region].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Smolensk State Medical University, Smolensk, Russia.
Objective: To study the quality of life (QoL) of patients with multiple sclerosis (MS) in the Smolensk region who receive MS disease-modifying therapies (DMT).
Material And Methods: The study included 37 patients receiving MS DMT. The 36-Item Short Form Health Survey (SF-36), the Multiple sclerosis Quality of Life (MusiQol), the Hamilton Depression Rating Scale, a scale of satisfaction with treatment, the Fatigue Severity Scale were administered.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!